ERYTHROMYCIN

Erythromycin Adverse Events Reported to the FDA Over Time

How are Erythromycin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Erythromycin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Erythromycin is flagged as the suspect drug causing the adverse event.

Most Common Erythromycin Adverse Events Reported to the FDA

What are the most common Erythromycin adverse events reported to the FDA?

Drug Interaction	281 (2.58%)
Vomiting	181 (1.66%)
Nausea	161 (1.48%)
Rash	157 (1.44%)
Dyspnoea	139 (1.28%)
Drug Exposure During Pregnancy	117 (1.08%)
Pyrexia	112 (1.03%)
Drug Hypersensitivity	111 (1.02%)
Drug Ineffective	111 (1.02%)
Diarrhoea	109 (1%)
Rhabdomyolysis	108 (.99%)
	Show More
Hypersensitivity	94 (.86%)
Urticaria	81 (.74%)
Abdominal Pain	76 (.7%)
Malaise	73 (.67%)
Caesarean Section	72 (.66%)
Headache	69 (.63%)
Intra-uterine Death	68 (.63%)
Pruritus	68 (.63%)
Abdominal Pain Upper	62 (.57%)
Asthenia	62 (.57%)
Dizziness	60 (.55%)
Sepsis	59 (.54%)
Oligohydramnios	58 (.53%)
Renal Failure Acute	58 (.53%)
Tremor	57 (.52%)
Thrombosis	55 (.51%)
Renal Failure	52 (.48%)
Drug Toxicity	50 (.46%)
International Normalised Ratio Incr...	50 (.46%)
Erythema	49 (.45%)
Fatigue	49 (.45%)
Abdominal Discomfort	45 (.41%)
Hyperhidrosis	45 (.41%)
Hypotension	44 (.4%)
Cough	43 (.4%)
Stevens-johnson Syndrome	42 (.39%)
Back Pain	41 (.38%)
Dysphagia	41 (.38%)
Oedema Peripheral	40 (.37%)
Confusional State	39 (.36%)
Convulsion	38 (.35%)
Dystonia	38 (.35%)
Brain Oedema	36 (.33%)
Chest Pain	36 (.33%)
Cholestasis	36 (.33%)
Condition Aggravated	36 (.33%)
Vision Blurred	36 (.33%)
Drug Dispensing Error	35 (.32%)
Hepatitis	35 (.32%)
Hyphaema	35 (.32%)
Iritis	35 (.32%)
Macular Oedema	35 (.32%)
Myalgia	35 (.32%)
Somnolence	35 (.32%)
Accidental Overdose	33 (.3%)
Anaemia	33 (.3%)
Haematemesis	33 (.3%)
Abdominal Distension	32 (.29%)
Alanine Aminotransferase Increased	32 (.29%)
Hepatic Failure	32 (.29%)
Jaundice	32 (.29%)
Accidental Exposure	31 (.29%)
Constipation	31 (.29%)
Medication Error	31 (.29%)
Pain	31 (.29%)
Agitation	30 (.28%)
Aspartate Aminotransferase Increase...	30 (.28%)
Hepatic Enzyme Increased	30 (.28%)
Liver Disorder	30 (.28%)
Respiratory Failure	30 (.28%)
Skin Disorder	30 (.28%)
Maternal Drugs Affecting Foetus	29 (.27%)
Movement Disorder	29 (.27%)
Pneumonia	29 (.27%)
Swelling Face	29 (.27%)
Cognitive Disorder	28 (.26%)
Dehydration	28 (.26%)
Rash Maculo-papular	28 (.26%)
Hypotonia	27 (.25%)
Paraesthesia	27 (.25%)
Syncope	27 (.25%)
Aphasia	26 (.24%)
Ascites	26 (.24%)
Foetal Arrhythmia	26 (.24%)
Hypertension	26 (.24%)
Rash Erythematous	26 (.24%)
Skin Exfoliation	26 (.24%)
Torsade De Pointes	26 (.24%)
Altered State Of Consciousness	25 (.23%)
Blood Creatine Phosphokinase Increa...	25 (.23%)
General Physical Health Deteriorati...	25 (.23%)
Jaundice Cholestatic	25 (.23%)
Stillbirth	25 (.23%)
Toxic Epidermal Necrolysis	25 (.23%)
Feeling Abnormal	24 (.22%)
Gestational Diabetes	24 (.22%)
Haemoglobin Decreased	24 (.22%)
Hallucination	24 (.22%)
Hepatic Function Abnormal	24 (.22%)
Pancreatitis	24 (.22%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Erythromycin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Erythromycin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Erythromycin

What are the most common Erythromycin adverse events reported to the FDA?

Epidermal And Dermal Conditions	681 (6.26%)
Gastrointestinal Signs	667 (6.13%)
Neurological	442 (4.06%)
Therapeutic And Nontherapeutic Effe...	440 (4.05%)
Respiratory	393 (3.61%)
Hepatic And Hepatobiliary	359 (3.3%)
Infections - Pathogen Unspecified	355 (3.26%)
Allergic Conditions	243 (2.23%)
Medication Errors	236 (2.17%)
Muscle	226 (2.08%)
Chemical Injury And Poisoning	213 (1.96%)
	Show More
Cardiac Arrhythmias	203 (1.87%)
Movement Disorders	194 (1.78%)
Hematology Investigations	182 (1.67%)
Gastrointestinal Motility And Defec...	170 (1.56%)
Renal Disorders	159 (1.46%)
Bacterial Infectious	144 (1.32%)
Ocular Infections, Irritations And ...	143 (1.31%)
Hepatobiliary	141 (1.3%)
Body Temperature Conditions	113 (1.04%)
Abortions And Stillbirth	112 (1.03%)
Cardiac And Vascular Investigations	108 (.99%)
Angiedema And Urticaria	107 (.98%)
Gastrointestinal Hemorrhages	89 (.82%)
Headaches	85 (.78%)
Obstetric And Gynecological Therape...	83 (.76%)
Musculoskeletal And Connective Tiss...	82 (.75%)
Embolism And Thrombosis	79 (.73%)
Seizures	74 (.68%)
Urinary Tract Signs	74 (.68%)
Placental, Amniotic And Cavity Diso...	73 (.67%)
Skin Appendage Conditions	72 (.66%)
Eye	70 (.64%)
Physical Examination Topics	69 (.63%)
Decreased And Nonspecific Blood Pre...	67 (.62%)
Vision	67 (.62%)
Oral Soft Tissue Conditions	65 (.6%)
Deliria	64 (.59%)
Anxiety Disorders	63 (.58%)
Injuries	61 (.56%)
Anemias Nonhemolytic And Marrow Dep...	60 (.55%)
Fatal Outcomes	60 (.55%)
White Blood Cell	60 (.55%)
Appetite And General Nutritional	56 (.51%)
Metabolic, Nutritional And Blood Ga...	56 (.51%)
Central Nervous System Vascular	55 (.51%)
Bronchial Disorders	53 (.49%)
Glucose Metabolism Disorders	53 (.49%)
Lower Respiratory Tract Disorders	53 (.49%)
Water, Electrolyte And Mineral	53 (.49%)
Upper Respiratory Tract Disorders	52 (.48%)
Neuromuscular	51 (.47%)
Electrolyte And Fluid Balance Condi...	50 (.46%)
Enzyme	50 (.46%)
Mental Impairment	50 (.46%)
Gastrointestinal Ulceration And Per...	46 (.42%)
Joint	46 (.42%)
Neonatal And Perinatal Conditions	44 (.4%)
Disturbances In Thinking	43 (.4%)
Fungal Infectious	42 (.39%)
Increased Intracranial Pressure And...	42 (.39%)
Procedural And Device Related Injur...	40 (.37%)
Suicidal And Self-injurious Behavio...	40 (.37%)
Ocular Hemorrhages And Vascular	38 (.35%)
Toxicology And Therapeutic Drug Mon...	38 (.35%)
Vascular	36 (.33%)
Exocrine Pancreas Conditions	34 (.31%)
Skin Vascular Abnormalities	34 (.31%)
Tongue Conditions	34 (.31%)
Cardiac Disorder Signs	33 (.3%)
Neurological, Special Senses And Ps...	32 (.29%)
Peritoneal And Retroperitoneal Cond...	32 (.29%)
Product Quality Issues	32 (.29%)
Protein And Chemistry Analyses	32 (.29%)
Hearing	31 (.29%)
Renal And Urinary Tract Investigati...	31 (.29%)
Maternal Complications Of Labour An...	30 (.28%)
Administration Site Reactions	29 (.27%)
Tissue	29 (.27%)
Coronary Artery	28 (.26%)
Pregnancy, Labour, Delivery And Pos...	28 (.26%)
Spleen, Lymphatic And Reticulendoth...	28 (.26%)
Personality Disorders	27 (.25%)
Vascular Hypertensive	26 (.24%)
Platelet	25 (.23%)
Arteriosclerosis, Stenosis, Vascula...	24 (.22%)
Gastrointestinal Conditions	24 (.22%)
Lifestyle Issues	24 (.22%)
Sleep Disorders	24 (.22%)
Cognitive And Attention Disorders	23 (.21%)
Hematological And Lymphoid Tissue T...	23 (.21%)
Ocular Neuromuscular	23 (.21%)
Pleural	23 (.21%)
Anterior Eye Structural Change, Dep...	22 (.2%)
Therapeutic Procedures And Supporti...	21 (.19%)
Viral Infectious	21 (.19%)
Aural	20 (.18%)
Gastrointestinal Stenosis And Obstr...	20 (.18%)
Nephropathies	20 (.18%)
Changes In Physical Activity	19 (.17%)
Gastrointestinal Inflammatory Condi...	19 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Erythromycin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Erythromycin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.